<scp>FAAH</scp> inhibitor <scp>URB597</scp> shows anti‐hyperalgesic action and increases brain and intestinal tissues fatty acid amides in a model of <scp>CRF<sub>1</sub></scp> agonist mediated visceral hypersensitivity in male rats
URB597 shows efficacy to elevate brain and intestinal FAAs and to counteract the colonic hypersensitivity induced by peripheral activation of CRF<sub>1</sub> signaling supporting a potential strategy of FAAH inhibitors to alleviate stress-related visceral hypersensitivity.
Authors
- Muriel Larauche (ORCID: https://orcid.org/0000-0003-3320-3675)
- Peter Germano (ORCID: https://orcid.org/0000-0002-6766-0885)
- Chrysanthy Ha (ORCID: https://orcid.org/0000-0002-3813-7227)
- Stacy D. Arnett
- Agata Mulak (ORCID: https://orcid.org/0000-0003-4678-8393)
- James P. Pearson (ORCID: https://orcid.org/0009-0001-5927-8395)
- Mulugeta Million
- Mark G. Currie (ORCID: https://orcid.org/0009-0007-2239-5014)
- Y. Taché
Institutions
- University of California, Los Angeles (US)
- VA Greater Los Angeles Healthcare System (US)
Publication Details
- Journal
- Neurogastroenterology & Motility
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1111/nmo.14927
- Citations
- 4
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.79
Funders
- U.S. Department of Veterans Affairs
- Kosciuszko Foundation
- Ironwood Pharmaceuticals, Incorporated
- National Institutes of Health